PRCP — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL725968	0.64	11/20
SCHEMBL71620	0.63	11/20
SCHEMBL91163	0.63	11/20
SCHEMBL690843	0.57	11/20
SCHEMBL205415	0.55	11/20
SCHEMBL691508	0.55	11/20
SCHEMBL203573	0.54	11/20
SCHEMBL205196	0.54	11/20
SCHEMBL563467	0.54	11/20
SCHEMBL563468	0.54	11/20
SCHEMBL205205	0.54	11/20
SCHEMBL691476	0.53	11/20
SCHEMBL691477	0.53	11/20
SCHEMBL625717	0.53	11/20
SCHEMBL625718	0.53	11/20
SCHEMBL625719	0.53	11/20
SCHEMBL690370	0.52	11/20
SCHEMBL564421	0.52	11/20
SCHEMBL564422	0.52	11/20
SCHEMBL203176	0.51	11/20

Clinical trials — most relevant to PRCP by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Evolocumab on Vascular Function	PHASE4	COMPLETED
Bovine Lactoferrin to Prevent and Cure Iron Deficiency and Iron Deficiency Anemia in Complicated Pregnancies	PHASE4	COMPLETED
Fluticasone and Salmeterol in Allergic Rhinitis	PHASE4	COMPLETED
Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Effect of Bitopertin on the Liver and on Levels of Protoporphyrin IX in Bile, Blood, Liver, and Stool in Patients With Erythropoietic Protoporphyria/X-linked Protoporphyria and Increased Liver Stiffness and/or Liver Enzymes at Baseline	PHASE1	WITHDRAWN
The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic Breast Cancer and Triple-negative Breast Cancer, a Novel Mechanism	EARLY_PHASE1	UNKNOWN
The Effect of Monoallelic Variants in the ALPL Gene on the Natural Course of Hypophosphatasia in Russia	nan	RECRUITING
Ovarian Reserve and Matrix Metalloproteinases	nan	COMPLETED
Study of Tissue, Blood, and Urine Samples From Patients With Advanced Prostate Cancer	nan	UNKNOWN
Respiratory Cathepsins, Proteases Inhibitors and Glycosaminoglycans (GAG) in Mucopolysaccharidosis	nan	COMPLETED
SRT in Comparison to ERT on Immune Aspects and Bone Involvement in Gaucher Disease	nan	UNKNOWN
Institution of an Italian Multicenter Database of Patients Affected by Diseases of Phosphate Metabolism	nan	NOT_YET_RECRUITING
Screening of Lysosomal Storage Disorders Diseases in Minority Groups	nan	UNKNOWN
The PORTRAIT Study	nan	UNKNOWN
Markers in Acute Pancreatitis-1	nan	COMPLETED
LRP1 and Colon Cancer	nan	UNKNOWN
Longitudinal Assessment of Atypical Tripeptidyl Peptidase 1 Enzyme Deficiency Patients	nan	ACTIVE_NOT_RECRUITING
Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients	nan	RECRUITING
Integrated Proteomic HPLC-ESI-MS Analysis of Salivary Peptides of Preterm Newborns: a Pilot Study	nan	COMPLETED
Genetic Studies of Lysosomal Storage Disorders	nan	ENROLLING_BY_INVITATION
The Natural History of Alpha-Mannosidosis	nan	COMPLETED
Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence	nan	WITHDRAWN
RCDP Natural History Study	nan	UNKNOWN
Correlation Between Serum Markers of Unstable Plaque and Virtual Histology of Unstable Plaque Visualized by IVUS	nan	COMPLETED
Role of Serum ADAM 17 (A Disintegrin And Metalloprotease 17) and Caspase 3 in Patients With Chronic Kidney Disease	nan	NOT_YET_RECRUITING
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Genetic Mechanisms of Chronic Obstructive Pulmonary Disease (COPD)	nan	COMPLETED
18F-DCFPyL PET/CT in High-grade Epithelial Ovarian Cancer (PET HOC)	nan	COMPLETED
Hydroxychloroquin (HCQ) in chILD of Genetic Defect	nan	COMPLETED
Unraveling Genetics of HypoPhosPhatasia (HPP Genetics)	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PRCP binder may also engage these)

Protein	Name	Similarity
Q7TMR0	—	1.000	Q7TMR0 →
Q5RBU7	—	1.000	Q5RBU7 →
Q2TA14	—	0.997	Q2TA14 →
Q9ZUG3	—	0.985	Q9ZUG3 →
Q1PF08	—	0.984	Q1PF08 →
Q1PF50	—	0.984	Q1PF50 →
Q9LEY1	—	0.982	Q9LEY1 →
O82229	—	0.981	O82229 →
Q9SFB5	—	0.981	Q9SFB5 →
P34676	—	0.981	P34676 →
Q9ZQQ0	—	0.981	Q9ZQQ0 →
Q9SV04	—	0.981	Q9SV04 →
Q9SV02	—	0.980	Q9SV02 →
Q9MAR8	—	0.980	Q9MAR8 →
P55748	—	0.980	P55748 →
Q84WF0	—	0.980	Q84WF0 →
Q9H3G5	—	0.980	Q9H3G5 →
Q9LSM9	—	0.980	Q9LSM9 →
Q9D3S9	—	0.979	Q9D3S9 →
Q8VY01	—	0.979	Q8VY01 →
W7DQR8	—	0.979	W7DQR8 →
Q9FH05	—	0.978	Q9FH05 →
Q60HF6	—	0.978	Q60HF6 →
GLB1	Beta-galactosidase	0.978	landscape →
P23780	—	0.977	P23780 →
Q4QR71	—	0.977	Q4QR71 →
Q0WPR4	—	0.977	Q0WPR4 →
CTSA	Lysosomal protective protein	0.977	landscape →
Q8S8K6	—	0.976	Q8S8K6 →
P45582	—	0.976	P45582 →